In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes

Blood

Volumn 108, Issue 5, 2006, Pages 1770-1773

  Park, Kyung Duk ^b   Marti, Luciana ^b   Kurtzberg, Joanne ^b   Szabolcs, Paul ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ARTICLE; CELL CULTURE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; UMBILICAL CORD BLOOD;

EID: 33748180203     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-10-006536     Document Type: Article

References (25)

1. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
2. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-1377.
3. Keever-Taylor CA, Margolis D, Konings S, et al. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. Biol Blood Marrow Transplant. 2001;7:247-256.
4. Einsele H, Rauser G, Grigoleit U, et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy. 2002;4:49-54.
5. Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005;105:2793-2801.
6. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10:143-155.
7. Kleihauer A, Grigoleit U, Hebart H, et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol. 2001;113:231-239.
8. Marchant A, Goldman M. T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol. 2005;141:10-18.
9. Goriely S, Vincart B, Stordeur P, et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol. 2001;166:2141-2146.
10. Langrish CL, Buddle JC, Thrasher AJ, Goldblatt D. Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin Exp Immunol. 2002;128:118-123.
11. Szabolcs P, Park KD, Marti L, et al. Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin. Biol Blood Marrow Transplant. 2004;10:772-783.
12. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med. 1997;186:1603-1608.
13. Schlienger K, Craighead N, Lee KP, Levine BL, June CH. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood. 2000;96:3490-3498.
14. Szabolcs P, Park KD, Reese M, Marti L, Broadwater G, Kurtzberg J. Coexistent naive phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp Hematol. 2003;31:708-714.
15. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-667.
16. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189:371-380.
17. Andreoni KA, Wang X, Huong SM, Huang ES. Human CMV-IGIV (CytoGam) neutralizes human cytomegalovirus (HCMV) infectivity and prevents intracellular signal transduction after HCMV exposure. Transpl Infect Dis. 2001;3(suppl 2):25-30.
18. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood. 2002;99:2913-2921.
19. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-1193.
20. - donors. Biol Blood Marrow Transplant. 2004;10:761-771.
21. Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol. 2004;65:486-492.
22. Le Roy E, Baron M, Faigle W, et al. Infection of APC by human cytomegalovirus controlled through recognition of endogenous nuclear immediate early protein 1 by specific CD4(+) T lymphocytes. J Immunol. 2002;169:1293-1301.
23. + T-cell effector differentiation by TGF-beta1 and 4-1BB costimulation. Blood. 2005;105:274-281.
24. + T cells in protection against CMV disease. Blood. 2003;101:2686-2692.
25. Hensel N, Melenhorst JJ, Bradstock K, et al. Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors. Cytotherapy. 2002;4:29-40.